215 related articles for article (PubMed ID: 26577210)
21. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
[TBL] [Abstract][Full Text] [Related]
22. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
23. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
24. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
25. [Sebaceous gland tumor with a rare gene mutation within a tumor syndrome: Muir-Torre syndrome].
Voigt E; Sommer F; Geiger KD; Pillunat LE
Ophthalmologe; 2014 Apr; 111(4):369-72. PubMed ID: 23774967
[TBL] [Abstract][Full Text] [Related]
26. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
27. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
29. DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma.
Rajan Kd A; Burris C; Iliff N; Grant M; Eshleman JR; Eberhart CG
Am J Ophthalmol; 2014 Mar; 157(3):640-7.e1-2. PubMed ID: 24321472
[TBL] [Abstract][Full Text] [Related]
30. Muir-Torre syndrome.
Navi D; Wadhera A; Fung MA; Fazel N
Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
[TBL] [Abstract][Full Text] [Related]
31. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
32. Aggressive Extraocular Sebaceous Carcinoma of the Scalp Involving the Brain in a Patient With Muir-Torre Syndrome.
Hadravsky L; Kazakov DV; Stehlik J; Michal M; Curik R; Krupa P; Skalova A; Kacerovska D
Am J Dermatopathol; 2016 Aug; 38(8):618-22. PubMed ID: 26779764
[TBL] [Abstract][Full Text] [Related]
33. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
[TBL] [Abstract][Full Text] [Related]
34. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
36. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
37. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.
Shalin SC; Lyle S; Calonje E; Lazar AJ
Histopathology; 2010 Jan; 56(1):133-47. PubMed ID: 20055911
[TBL] [Abstract][Full Text] [Related]
38. [Muir-Torre syndrome associated with Waldenstrom's macroglobulinemia].
Velter C; Bourlond F; Wettle C; Lioure B; Lipsker D; Maugard C; Cribier B
Ann Dermatol Venereol; 2016 Dec; 143(12):825-830. PubMed ID: 27771121
[TBL] [Abstract][Full Text] [Related]
39. Muir-Torre syndrome: case report and review of the literature.
Ang JM; Alai NN; Ritter KR; Machtinger LA
Cutis; 2011 Mar; 87(3):125-8. PubMed ID: 21488569
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]